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Background: Microglial cells are resident macrophages of the central nervous system and important cellular mediators
of the immune response and neuroinflammatory processes. In particular, microglial activation and communication
between microglia, astrocytes, and neurons are hallmarks of the pathogenesis of several neurodegenerative diseases.
Membrane proteins and their N-linked glycosylation mediate this microglial activation and regulate many biological
process including signal transduction, cell-cell communication, and the immune response. Although membrane
proteins and N-glycosylation represent a valuable source of drug target and biomarker discovery, the knowledge of
their expressed proteome in microglia is very limited.
Results: To generate a large-scale repository, we constructed a membrane proteome and N-glycoproteome from BV-2
mouse microglia using a novel integrated approach, comprising of crude membrane fractionation, multienzyme-
digestion FASP, N-glyco-FASP, and various mass spectrometry. We identified 6928 proteins including 2850 membrane
proteins and 1450 distinct N-glycosylation sites on 760 N-glycoproteins, of which 556 were considered novel
N-glycosylation sites. Especially, a total of 114 CD antigens are identified via MS-based analysis in normal conditions of
microglia for the first time. Our bioinformatics analysis provides a rich proteomic resource for examining microglial
function in, for example, cell-to-cell communication and immune responses.
Conclusions: Herein, we introduce a novel integrated proteomic approach for improved identification of membrane
protein and N-glycosylation sites. To our knowledge, this workflow helped us to obtain the first and the largest
membrane proteomic and N-glycoproteomic datesets for mouse microglia. Collectively, our proteomics and
bioinformatics analysis significantly expands the knowledge of the membrane proteome and N-glycoproteome
expressed in microglia within the brain and constitutes a foundation for ongoing proteomic studies and drug
development for various neurological diseases.
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Microglia, which are representative immune cells in the
relatively immune-privileged central nervous system
(CNS), mediate immune and inflammatory responses in
the brain [1,2]. In response to pathological events, such
as immunological stimuli, neuronal injury, and tissue* Correspondence: biolab@snu.ac.kr
†Equal contributors
1Department of Biomedical Sciences, Seoul National University College of
Medicine, 28 Yongon-Dong, Seoul 110-799, Korea
2Institute of Medical & Biological Engineering, Medical Research Center, Seoul
National University College of Medicine, 28 Yongon-Dong, Seoul 110-799, Korea
© 2014 Han et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordamage, microglia alter their morphology, migrate to le-
sion sites, and proliferate [2,3]. Proliferating microglia
phagocytose pathogens, dying neuronal cells, lympho-
cytes, and other debris [3] and release a wide range of
soluble factors, including cytokines, chemokines, and
oxygen radicals, to maintain homeostasis in the micro-
environment and to support injured neurons in the
brain [3-5].
Due to their function in immune and inflammation re-
sponses in the brain, microglia are recently considered
central mediators in various neurological diseases, such
as HIV-1-associated dementia, Alzheimer disease (AD),. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trauma, stroke, and autoimmune CNS disease [6,7].
Microglia communicate actively with neurons and astro-
cytes in the brain. This communication is essential for the
maintenance of homeostasis in the brain and for appropri-
ate immune responses to microenvironmental alterations
[8]. Membrane proteins and their N-glycosylation mediate
this communications, which regulates many functions,
such as signal transduction, subcellular compartmentaliza-
tion, membrane trafficking, and immune responses [9].
The molecular and cellular interactions between these
proteins and their modification enable the cells to sense
micro environmental variations and activate various
mechanisms, including signaling pathways and transcrip-
tional regulation of specific genes.
Based on the function in molecular and cellular inter-
actions, membrane proteins and their glycosylation are
considered significant with regard to disease markers
and drug treatment targets, accounting for nearly 70% of
pharmaceutical drug targets and biomarkers [10,11].
Thus, to understand microglial function in the micro-
environment of the brain under normal and pathogenic
conditions and develop therapeutic targets and bio-
markers for neurological diseases, we must identify all
such membrane proteins and N-glycoproteins. Although
several proteomics studies have been performed in
microglia [12-15], membrane proteins and N-linked gly-
coproteins have not been examined in microglia in great
detail.
Mass spectrometry (MS)-based proteomic methods
have emerged as powerful and universal tools to exam-
ine proteins and their properties [16]. Specifically, large-
scale studies of membrane proteins and posttranslational
modifications (PTMs) are core subjects in MS-based
proteomics [17-19]. However, such studies continue to
face technically challenges in determining the abun-
dance, state of modification, and localization of proteins,
due to several factors, including the solubility, abun-
dance, digestion, and enrichment of membrane proteins
and N-glycosylated peptides [20,21]. Thus, analytical strat-
egies that are coupled with efficient methods, including
enrichment, solubilization, and digestion of membrane
proteins and N-glycoproteins, must be formulated.
Recently, sample preparation methods, such as filter-
aided sample preparation (FASP) [22,23] and multienzyme
digestion-FASP (MED-FASP) [24], have been developed
to deplete sodium dodecyl sulfate (SDS), maximizing the
solubility of membrane proteins. In addition, FASP-based
N-glycopeptide enrichment (N-glyco-FASP) was devel-
oped to facilitate the identification of many glycoproteins
[18]. These FASP-based methods have been used by sev-
eral studies to improve the identification of total proteins,
membrane proteins, N-glycoproteins, and other modifica-
tions [18,24-27].In this study, we generated large-scale data on the
membrane proteome and N-glycoproteome of the BV-2
microglia line by liquid chromatography-coupled tan-
dem mass spectrometry (LC-MS/MS) without extensive
peptide fractionation and examined the properties of the
resulting proteins with regard to membrane localization
and N-glycosylation. To derive a comprehensive mem-
brane proteome and N-glycoproteome from BV-2 cells,
we analyzed several replicates on various mass spectro-
metric instruments using multiple strategies, based on
recent advances in proteomics technologies, such as
crude membrane fractionation, FASP-based differential
sample preparation, and N-glyco-FASP-based glycopep-
tide enrichment.
We present the most detailed microglia membrane
proteome and N-glycoproteome dataset, resulting in
the identification of 6928 unique protein groups and
1450 unique N-glycosites from 82 LC-MS runs. In
addition, we characterized the membrane proteome
and N-glycoproteome of BV-2 cells using various bio-
informatics tools to classify functional groups and activ-
ities in microglia. This extensive profile, based on our
novel approach, constitutes a reference repository of
microglial membrane proteins and N-glycosylated pro-
teins, which will be particularly useful for future functional
and targeted proteomics studies in microglia.
Methods
Reagents and materials
HPLC-grade acetonitrile (ACN), HPLC-grade water,
HPLC-grade methanol, hydrochloric acid (HCl), and so-
dium chloride (NaCl) were obtained from DUKSAN
(Gyungkido, Korea). The BCA protein assay kit was pur-
chased from Pierce (Hercules, CA), and Complete Prote-
ase Inhibitor Cocktail Mini Tablets were purchased from
Roche (Mannheim, Germany). Dithiothreitol (DTT) and
urea were purchased from AMRESCO (Solon, OH).
PMSF, Sodium dodecyl sulfate (SDS) and Tris were pur-
chased from USB (Cleveland, OH). Sequencing-grade
modified trypsin and LysC were purchased from Promega
Corporation (Madison, WI) and Wako (Osaka, Japan),
respectively.
All other reagents—concanavalin A (ConA), wheat germ
agglutinin (WGA), Ricinus communis agglutinin 120
(RCA120), 2-mercaptoethanol, ammonium bicarbonate
(NH4HCO3), sucrose, EDTA, formic acid, iodoacetamide
(IAA), trifluoroacetic acid (TFA), PNGase F, and stable
isotope-labeled water (H2
18O, 99% atom% 18O)—were
purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture
Mouse microglia (BV-2 cell line) were maintained in DMEM
complete media, containing 5% (v/v) heat-inactivated FBS,
4 mM glutamine, 100 U/mL penicillin, and 100 mg/mL
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5% CO2.Crude membrane preparation
Crude membrane fractions were prepared using 4 differ-
ent methods (CM method 1, CM method 2, KIT 1, and
KIT 2). In CM method 1, membrane proteins were ex-
tracted as described with some modifications [28]. BV-2
cell pellets (1×107 cells) were homogenized in 1 ml high-
salt buffer (2 M NaCl, 10 mM HEPES-NaOH, pH 7.4,
1 mM EDTA, and 1X protease inhibitor cocktail) using
a syringe with a 261/2-gauge needle. The lysate was cen-
trifuged at 17,500 g at 4°C for 30 min. The pellet was
dissolved in 1 ml carbonate buffer (0.1 M Na2CO3,
pH 11.3, 1 mM EDTA, and 1X protease inhibitor cock-
tail), incubated on ice for 30 min, and centrifuged at
17,500 g for 30 min at 4°C. Incubation and centrifuga-
tion were repeated with carbonate buffer. After centrifu-
gation (17,500 g, 30 min at 4°C), the pellet was stored at
−80°C until further analysis.
In CM method 2, membrane proteins were prepared
as described with the following adaptations [29]. BV-2
cell pellets (1×107 cells) were homogenized in 1 ml STM
solution (0.25 M sucrose, 10 mM Tris–HCl, 1 mM
MgCl2, and 1X protease inhibitor cocktail) using a syr-
inge with a 261/2-gauge needle. Nuclei and tissue debris
were removed by centrifugation at 260 g for 5 min at 4°C.
The supernatant was first centrifuged at 1500 g for 10 min
at 4°C to pellet the crude membrane proteins. The pellet
was then mixed with 0.7 ml STM solution and centrifuged
at 16,000 g for 1 h at 4°C to purify the membrane pellet.
The pellet was washed in 1 ml of 0.1 M Na2CO3, pH 11
overnight at 4°C. After centrifugation at 16,000 g for 1 h at
4°C, the purified membrane pellet was stored at −80°C for
further processing. In contrast to other protocols [28,29],
all crude membrane protein pellets were solubilized with
strong SDS extraction buffer and subjected directly to di-
gestion by FASP.
Crude membrane fractionation using Commercial kits
(KIT 1 and KIT 2) were performed according to the
manufacturer’s instructions.Protein multienzyme digestion by FASP (MED-FASP)
Multiple-step enzyme digestion using filter-aided sample
preparation (MED-FASP) was performed as described
[22-24,26]. First, pellets that contained the crude mem-
brane fractions were resuspended in 200 μL strong SDS
extraction buffer (100 mM Tris pH 7.4, 4% SDS, and
0.1 M DTT). Protein concentration was measured using
a BCA assay kit. Approximately 200 μg of proteins was
mixed with 200 μl UA solution (8 M urea in 0.1 M Tris/
HCl pH 8.5), loaded onto a 30 k Microcon filtration unit
(Millipore), and centrifuged at 14,000 g for 20 min at 20°C.The concentrates were diluted in the devices with 200 μL
UA solution and centrifuged again.
Next, the concentrates were mixed with 200 μL IAA
solution (50 mM iodoacetamide in UA solution), and in-
cubated in the dark at room temperature (RT) for
30 min, and centrifuged for 15 min. Then, the concen-
trate was diluted with 200 μL UB solution (8 M urea in
0.1 M Tris/HCl, pH 8.5) and concentrated again. The
concentrate with UB solution was washed 3 more times.
After the flowthrough was discarded, 0.2 mL 50 mM
ABC was added to the filter and centrifuged at 14,000 g
for 15 min; this step was repeated 3 times.
Proteins were digested at 37°C overnight using LysC
(enzyme-to-substrate ratio [w/w] of 1:50) or trypsin (en-
zyme to substrate ratio [w/w] of 1:100). After an overnight
incubation at 37°C, the filtration unit was transferred to
new collection tubes, and the digested peptides were col-
lected by centrifugation for 20 min. Before the next diges-
tion step, the filtration units were washed once with 40 μl
UA solution and then with 2 40-μl washes with water. In
the second digestion, 100 μl 50 mM ABC with trypsin
(enzyme:protein ratio 1:100) was added to the filter units.
After an overnight incubation at 37°C, the filtration unit
was transferred to new collection tubes, and peptides were
collected by centrifugation for 20 min. Finally, the pep-
tides that were retained by the MWCO membrane in the
filtration units were eluted with 50 μl 0.5 M NaCl to en-
hance the yield of the digested protein. All resultant pep-
tides were acidified with 1% TFA and dried in a vacuum
centrifuge.
Prior to LC-MS/MS analysis, all dried peptide mixtures
were dissolved in 0.1% TFA and desalted using homemade
StageTips, as follows. Self-packed C18 microcolumns were
prepared by reversed-phase packing POROS 20 R2 mater-
ial (Applied Biosystems, Foster City, CA) into 200-μl yel-
low pipette tips on top of C18 Empore disk membranes.
The microcolumns were washed 3 times with 100 μl 100%
ACN and equilibrated 3 times with 100 μl 0.1% TFA by
applying air pressure from a syringe. After the samples
were loaded, the microcolumns were washed 3 times with
100 μl 0.1% TFA, and peptides were eluted with 100 μl of
a series of elution buffers, containing 0.1% TFA and 40%,
60%, and 80% ACN. All eluates were combined, dried in a
vacuum centrifuge, and stored at −80°C until further
analysis.
Whole-cell lysate capture by N-glyco-FASP
N-glycosylated peptides were enriched by N-glyco-FASP
[18]. In brief, BV-2 cells were cultured as described
above, washed 3 times with PBS, harvested, and pelleted
at 1000 g at 4°C. The pellets, containing 1×107 cells, were
dissolved in strong SDS extraction buffer. After measur-
ing the total protein concentration by BCA assay, 300 μg
of proteins was digested per the FASP protocol above.
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(20 mM Tris pH 7.6, 1 mM MnCl2, 1 mM CaCl2, and
0.5 M NaCl) and transferred to new TM-30 filter units
(Microcon, Millipore).
Lectin solution, containing ConA (100 μg), WGA
(100 μg), and RCA120 (80 μg), was added to the filter
units. After one-hour incubation at room temperature,
the unbound peptides were eluted by centrifugation at
14,000 g for 10 min. The captured fractions were washed
several times with lectin binding solution and concen-
trated by centrifugation. To remove ordinary water
(H2
16O) and adjust the pH, concentrated peptides were
washed twice with 50 μl ABC18O solution (40 mM ABC
in H2
18O). After the filter units were transferred to new
collection tubes, PNGase F (2U in 40 μl ABC18O) was
added to glycan-containing peptides in the filter units.
The mixture was incubated at 37°C for 3 hr, and the de-
glycosylated peptides were eluted.
Crude membrane fraction capture by N-glyco-FASP
As described above, crude membrane fractions of BV-2
cells were extracted using CM method 1 and CM method
2 and solubilized with strong SDS extraction buffer. After
the concentration of crude membrane proteins was mea-
sured, 150 μg of proteins from each CM method was
mixed 1:1 and processed by FASP. N-glycopeptides were
enriched by N-Glyco-FASP, as described above.
LC-MS/MS analysis
The peptide samples were analyzed by LC-MS on an
Easy-nLC (Thermo Fisher Scientific, Odense, Denmark)
that was coupled to a nanoelectrospray ion source
(Thermo Fisher Scientific, Bremen, Germany) on an LTQ
Velos, LTQ-Orbitrap Velos, or Q Exactive mass spec-
trometer (all from Thermo Fisher Scientific, Bremen,
Germany). Peptides were separated on the 2-column setup
with a trap column (100 μm I.D. × 3 cm) and an analytic
column (75 μm ID × 15 cm) that was packed in-house
with C18 resin (Magic C18-AQ 200 Å, 5 μm particles).
Solvent A was 0.1% v/v formic acid and 2% acetonitrile,
and solvent B was 98% acetonitrile with 0.1% v/v formic
acid.
In the experiments for the crude membrane proteome,
a 200-min 5% to 40% solvent B gradient was run for the
initial enzyme-digested samples in MED-FASP and sam-
ples that were derived from single-FASP. A 140-min 5%
to 40% solvent B gradient was applied to the second set
of enzyme-digested samples in the MED-FASP proced-
ure. In experiments on the N-glycoproteome, 3 quadru-
plicate runs were performed with 140 min 5% to 40%
solvent B gradient. A 200-min 5% to 40% solvent B gra-
dient was applied to the last quadruplicate run.
The spray voltage was 1.8 kV in the positive ion mode,
and the temperature of the heated capillary was 325°C.Mass spectra were acquired in a data-dependent manner
using a top 10 method. For low-resolution mass spec-
trometry on an LTQ velos, a cycle of 1 full-scan MS sur-
vey spectra (m/z 300–1800) was acquired in the profile
mode. For high-resolution mass spectrometry, MS spec-
tra were acquired on an Orbitrap analyzer with a mass
range of 300–1800 m/z and 60,000 resolution at m/z
400 (Orbitrap Velos) or 300–1800 m/z and 70,000 reso-
lution at m/z 200 (Q Exactive). HCD scans were ac-
quired in Q Exactive at a resolution of 15,000. CID
peptide fragments were acquired at 35 normalized colli-
sion energy (NCE) for the LTQ velos and Orbitrap velos,
and HCD peptide fragments were acquired at 27 NCE.
Data analysis for low-resolution (LR) instrument
The MS/MS spectra data from the LTQ velos were proc-
essed using the SEQUEST Sorcerer 2 platform (Sage-N
Research, Milpitas, CA, USA) as described [26]. MS/MS
data were searched using a target-decoy database search
strategy against a composite database that contained the
International Protein Index (IPI) mouse database (v3.78,
59,534 entries), and its reverse sequences were generated
using Scaffold 3 (Proteome Software Inc, Portland, OR).
The database search parameters were: full enzyme digest
using trypsin (After KR/-) with up to 2 missed cleavages; a
precursor ion mass tolerance of 1.0 Da (average mass) for
glycopeptide identification; a fragment ion mass tolerance
of 0.5 Da (monoisotopic mass); a static modification of
57.02 Da on Cys residues for carboxyamidomethylation;
and a variable modification of 15.99 Da on Met residues
for oxidation and, +2.99826 Da on Asn residues for 18O-
deamidation. For analysis of the N-glycoproteome, the
database search output results were validated using
Trans-Proteome Pipeline (TPP), version 4.5 with the
PeptideProphet and ProteinProphet algorithms [30].
Data analysis for high-resolution (HR) instruments
The MS data from the LTQ Orbitrap Velos were proc-
essed in MaxQuant, version 1.2.2.5 [31] using the An-
dromeda search engine [32]. Precursor MS signal
intensities were determined, and CID or HCD MS/MS
spectra were deisotoped and filtered such that only the 6
most abundant fragments per 100 m/z range were
retained. Protein groups were identified by searching the
MS and MS/MS data of peptides against the IPI mouse
database (v3.78, 59,534 entries), containing both forward
and reversed protein sequences. For peptides that were
obtained with LysC, LysC/P specificity was used. Data
that were obtained from the analysis of trypsin-digested
peptides were searched for trypsin/P specificity. The
database search parameters were as follows: the initial
precursor, CID fragment mass tolerances, HCD fragment
mass tolerances were set to 7 ppm, 0.5 Da, and 20 ppm,
respectively; up to 2 missed cleavages were allowed;
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cation; oxidation of Met, acetylation of protein N-term,
and, if required, 18O-deamidation of Asn were applied
as variable modifications. Leucines were replaced by
isoleucines.
All peptides, modification sites, and protein identifica-
tions were filtered at a false discovery rate (FDR) < 1%.
To specify the FDR independently for peptides and pro-
teins, peptides that belonged to proteins that did not
meet the FDR threshold were removed from the dataset.
Peptides were assigned to protein groups, rather than
proteins. To compare protein lists between datasets, 1
representative protein of a group was defined as the lead
protein, which is described in Additional file 1: Table S1
and Additional file 2: Tables S2 and S3.Bioinformatics analysis
Gene ontology analysis was performed using Cytoscape
[33] and Plugin BiNGO 2.4 [34], the UniprotKB database
[35], and the PANTHER database [36]. Pathway analysis
and interaction network analysis were performed using the
KEGG (Kyoto Encyclopedia of Genes and Genomes) path-
ways database (http://www.genome.jp/kegg), PANTHER
pathway [36], and the DAVID bioinformatics tool [37].Figure 1 Flowchart for analysis of crude membrane proteome and N-
performed using 2 schemes. Crude membrane fractions, obtained from CM m
or single-FASP. Peptides were analyzed by reverse-phase LC-MS/MS and high
N-glycopeptides, N-glyco-FASP was performed on whole-cell lysates or crude
proteins with FDR < 1%. Overlap between the 2 proteomes is shown (light bl
proportional Venn diagram for proteins identified as GO term “membrane” an
overlap between 2 proteomes is shown as a Venn diagram (light blue: crude
domain,” the overlap between the 2 proteomes is shown as a Venn diagramThe details of each bioinformatics tool are described in
Additional file 3.Validation of method by western blot
To verify the crude membrane fractionation methods,
control samples and crude membrane fraction samples
that were prepared using the 4% SDS, KIT, and CM
methods were separated by SDS-PAGE in 8% polyacryl-
amide gels and transferred to a PVDF membrane for
western blot analysis. Details of the western blot analysis
are described in Additional file 3.Results and discussion
Overall experimental workflow for membrane proteome
and N-glycoproteome
To achieve maximum coverage of the membrane prote-
ome and N-glycoproteome in a reasonable time, we per-
formed a novel proteomic analysis using a combination
of crude membrane (CM) fractionation and protein di-
gestion strategies without extensive peptide fractionation
(Figure 1A). First, crude membrane proteins were pre-
pared using 4 methods (CM methods 1–2 and KITs 1–2).
Briefly, 200 μg of the CM fractions from CM methods 1
and 2 was digested by MED-FASP. In the first digestion,glycoproteome in BV-2 microglia cell line. (A) Experiments were
ethods 1 and 2, KITs 1 and 2, and 4% SDS, were digested by MED-FASP
-resolution mass spectrometry (Orbitrap Velos and Q Exactive). To enrich
membrane fractions. (B) Area-proportional Venn diagram for all identified
ue: crude membrane proteome; orange: N-glycoproteome). (C) Area-
d transmembrane domain-containing proteins. For “GO:membrane,” the
membrane proteome; red: N-glycoproteome). For “transmembrane
(light blue: crude membrane proteome; green: N-glycoproteome).
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methods 1 and 2, yielding 2 digests. In the second diges-
tion, trypsin was then added to these digests, yielding 2
additional digested solutions. Ultimately, CM methods 1
and 2 yielded 4 fractions that were analyzed in 4 separate
LC-MS/MS runs. For example, the combination of the
CM fractionation method and 2-step digestions generated
4 datasets for CM method 1: MED(LysC/trypsin)_1st
(LysC), MED(LysC/trypsin)_2nd(Trypsin), MED(trypsin/
trypsin)_1st(trypsin), and MED(trypsin/trypsin)_2nd(trypsin).
Next, crude membranes that were extracted using
commercial kits (KIT 1 and 2) were processed by single-
FASP. In addition, whole-cell lysates that were processed
using single-FASP were analyzed as a control set (4%
SDS). Consequently, we generated 2 biological sets of a
crude membrane proteome using CM methods 1 and 2
and KIT 1 and 2 and whole cell lysates (Additional file 1:
Table S1). Two biological sets were analyzed using several
data acquisition strategies (HR-CID and HR-HCD), based
on 2 mass spectrometry platforms (Orbitrap Velos and Q
Exactive, respectively). MS/MS spectra from the HR in-
struments were analyzed using Maxquant [31] and the
Andromeda search engine [32]. Finally, the resulting
data were integrated into large and heterogeneous data-
sets (Additional file 1: Table S1 and Additional file 2:
Tables S2 and S3).
To describe the N-glycoproteome of BV-2 cells, whole-
cell lysate capturing (WCC) was first processed using the
N-Glyco-FASP protocol with multi-lectin enrichment and
18O-water [18]. To obtain a wide range of glycopeptides
and improve the coverage of the N-glycoproteome, an
additional analysis was performed by crude membrane
fraction capturing (CMC), a method that is based on
capturing N-glycopeptides from crude membrane frac-
tions using a combination of CM methods 1 and 2 and
N-glyco-FASP. Briefly, glycopeptides that were enriched
from 300 μg of whole-cell lysates were analyzed on an
Orbitrap Velos and Q Exactive. Also, glycopeptides that
were captured from 300 μg of crude membrane fractions
were analyzed on an LTQ Velos. Two biological replicates
for WCC and CMC were analyzed to maximize coverage
of the BV-2 N-glycoproteome. Raw files from the WCC
were processed using the Maxquant-Andromeda platform,
and CMC data were processed on the Sorcerer-Sequest
platform. Detailed procedures of the data processing are
described in Additional file 3. Detailed procedures of all
experiments and an overview of the final datasets are
shown in Figure 1A and Additional file 4: Figure S1.
Using all stringently filtered peptides, 6928 unique
proteins were identified from 82 LC-MS/MS runs at a
false discovery rate (FDR) of 1% (Figure 1B). Combining
LC-MS data from the experiments for the crude mem-
brane proteome, we identified 6668 unique proteins with
a 1% FDR. In the whole-cell proteome, 3806 uniqueproteins were identified with a 1% FDR. Combining data
from the quadruplicate analysis of N-glycosylated pep-
tides per biological repeat, we obtained 760 glycoproteins
from 1450 unique N-glycosylation sites with a 1% FDR
that incorporated 18O-deamidated asparagine and the
N-glycosylation sites of which were consistent with the
canonical N!P-[S/T/rarely C] motif. As shown Figure 1C,
we identified 2850 proteins that were annotated with the
GO term “membrane.” Also, 2367 proteins were identi-
fied as transmembrane domain (TMD)-containing pro-
teins in all experiments. All identification data are listed
in Additional file 2: Tables S2 and S3, Additional file 5:
Tables S4 nd S5, Additional file 6: Tables S6 and S7,
Additional file 7: Table S8.General characterization of membrane proteins from BV-2
cells
In our analysis of the crude membrane proteome, com-
prising 66 LC-MS/MS runs, 6668 protein groups were
identified at an FDR of 1%. Biological sets 1 and 2 re-
sulted in the identification of 5900 and 5603 unique pro-
tein groups, respectively (Figure 2A). Approximately
70% of identified proteins were common to all 2 bio-
logical sets. In biological sets 1 and 2, the average An-
dromeda identification score was 121.7 and 105.5,
respectively. The absolute mass deviation ranged from
0.29 ppm to 0.60 ppm for the identified peptides in bio-
logical set 1 and 2 (Additional file 1: Table S1).
To determine the reproducibility of our analysis, cor-
relations between protein abundance were examined in
the technical replicates and biological replicates. In bio-
logical sets 1 and 2, protein abundance was calculated
by summing the intensities of all peptides that were
assigned to a protein. We first examined the correlation
between technical replicates in each experiment. The
correlation analysis of the other experiments is summa-
rized in Additional file 4: Figure S2. Overall, the tech-
nical and biological variations in all experiments were
minor (median R = 0.982 in technical replicates and me-
dian R = 0.687 in biological replicates), indicating that
the crude membrane fractionation and peptide prepar-
ation methods and the mass spectrometric analysis had
robust and reasonable reproducibility.
Next, we searched for the presence of specific character-
istics in all identified membrane proteins. The crude
membrane fractions were enriched for authentic mem-
brane proteins. Cellular compartments of the identified
proteins were analyzed using the DAVID [37], BinGO
[34], and UniprotKB databases [35]. We noted that 40% to
60% of all identified proteins were bona fide membrane
proteins, regardless of mass spectrometric method. A sub-
sequent analysis using TMD prediction programs (SCAMPI
[38], TMHMM 2.0 [39], and SOSUI [40]) suggested that
Figure 2 Identification and characterization of crude membrane proteome. (A) Overlap between proteins identified from 2 biological sets.
The number of unique protein groups and the corresponding gene symbols identified from the 2 biological sets are described. The number of
nonredundant genes that were identified from each biological set is shown in parentheses. (B) Percentage of identified proteins by functional
category. All identified proteins in the 2 biological replicates were grouped into 6 categories: total identified proteins (Total I.D), proteins annotated as
GO term “membrane” (GO:membrane), proteins annotated as GO term “integral to membrane” (GO:integral to membrane), proteins annotated as GO
term “plasma membrane” (GO:plasma membrane), transmembrane domain (TMD)-containing proteins, and proteins with GRAVY score above 0
(GRAVY > 0). The total number of proteins identified in each category is indicated on the right of the bar. Blue bars represent percentage of proteins
identified in all 2 biological sets. Red and green bars indicate percentage of proteins detected only in biological sets 1 and 2, respectively. (C) Distribution
of number of unique proteins versus the number of predicted transmembrane domains. (D) Distribution of grand average hydrophobicity (GRAVY)
score and molecular weight (MW) of proteins identified in the 2 biological replicates. Y-axis is the GRAVY score value, and the x-axis represents
logarithmic molecular weights of the identified proteins. The GRAVY scores and log MW of 2164 transmembrane domain (TMD)-containing proteins,
merged from 2 biological sets, are plotted as edged blue circles.
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http://www.biomedcentral.com/1471-2164/15/9530% to 50% of identified membrane proteins contained at
least 1 TMD (Additional file 4: Figure S3A).
We examined the overlap in membrane proteins
and all identified proteins between the 2 biological
sets (Figure 2B)—1987 membrane proteins were com-
monly identified as GO:membrane in the 2 biological
sets, indicating that 72.5% of such proteins over-
lapped. Further, of 1672 proteins that were identified
as integral membrane proteins, 305 (18.4%) and 128
(7.7%) appeared only in biological sets 1 and 2, re-
spectively. Also, 1561 (72%) of 2164 TMD proteins
overlapped in the 2 biological sets. Notably, the per-
centage of overlap in hydrophobic proteins with a
GRAVY score above 0 was 78%, suggesting that crudemembrane fractionation is suitable for enriching mem-
brane proteins with high hydrophobicity.
The distribution of identified membrane proteins
across the number of predicted TMDs is shown in
Figure 2C. Because different informatics tools for TMD
prediction have disparate outputs regarding the number
and topology of the predicted TMD regions [41], several
programs should be considered to provide a more
comprehensive view of a membrane proteome. Thus, the
representative number of predicted TMDs for each pro-
tein was defined as the highest value from SCAMPI [38],
TMHMM 2.0 [39], and SOSUI [40]. Approximately 70%
of all identified TMD proteins had 2 or more predicted
TMDs, and 20% had 7 or more TMDs. Ten percent of
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One protein (Fam38a), which had 38 predicted TMDs,
was identified as Piezo-type mechanosensitive ion channel
component 1 (Additional file 2: Tables S2 and S3).
We also analyzed the characteristics of our crude
membrane proteome, such as protein size (MW) and
hydrophobicity (GRAVY). As seen in Figure 2D, of the
6668 proteins from the 2 biological replicates, 1245
(19%) had an MW> 100 kDa and 877 (13%) had
GRAVY > 0. The highest MW and GRAVY score in our
proteome were 3901 kDa and 1.14, respectively. The
average MW and GRAVY score of all identified proteins
in the crude membrane proteome were 70.4 kDa and
−0.368, respectively, versus 72.3 kDa and −0.10 in the
2379 TMD-containing proteins, respectively. Most (90%)
proteins with a GRAVY score > 0 harbored TMDs, which
is consistent with the high hydrophobicity of the TMD.
Identification of BV-2 N-glycoproteome
In analysis of BV-2 N-glycoproteome, we identified 1450
unique N-glycosites and 760 unique glycoproteins byFigure 3 Proteomic characterization of BV-2 N-glycoproteome. (A) Ov
circle: crude membrane fraction capturing). (B) Identification of N-glycosylatio
Orange bars and green bars represent the number of N-glycosylation sites an
N-x-T and N-x-S in all experiments. (D) Distribution of singly and multiply N-gWCC and CMC after removing the redundancy from all
datasets and selecting N-glycopeptides that contained
the canonical motif (Figure 3A and Table 1). We also
identified 605 distinct N-glycosites for 330 unique glyco-
proteins by WCC and 1267 distinct N-glycosites for 671
unique glycoproteins by CMC; 422 N-glycosites from
241 glycoproteins were common in both approaches
(Figure 3A and Additional file 4: Figure S4).
As shown in Additional file 4: Figure S5, the technical
variation between all replicates was reasonable (overlap
of 45% to 74% for unique N-glycosites and overlap of
52% to 81% for unique glycoproteins). In addition, ap-
proximately 44% of N-glycosites and 48% of glycopro-
teins overlapped between biological replicates by WCC.
By CMC, 70% of unique N-glycosites and 69% of glyco-
proteins overlapped between replicates.
Although the inclusion of technical and biological repli-
cates increased the coverage of the BV-2 N-glycopro-
teome, the technical and biological reproducibility ranged
widely. The variability between types of mass spectro-
meters, differences in LC-gradient between technicalerlap between 2 approaches (blue circle: whole cell capturing; red
n sites and N-glycoproteins in 16 replicates by 2 different approaches.
d N-glycoproteins, respectively. (C) Frequency of consensus sequence
lycosylated proteins.
Table 1 Coverage of BV-2 N-glycoproteome by various approaches













WCC Biological replicate 1 1250 545 297 1052 396 231
Biological replicate 2 1501 576 305 1342 473 257
Combined 2751 845 441 2394 605 330
CMC Biological replicate 1 9536 1958 927 7380 1111 594
Biological replicate 2 7223 1760 845 5509 1017 538
Combined 16759 2420 1116 12889 1267 671
Total 1450 760
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aration methods might have resulted in imperfect repro-
ducibility between technical and biological replicates.
However, in combining all replicates, the difference in the
number of glycosylation sites that were identified in each
replicate reflects an important advantage with regard to
the number of unique identifications; thus, our experi-
ments enhanced the coverage of the N-glycoproteome as
much as possible.
As shown in Figure 3B, CMC identified significantly
more N-glycosites and glycoproteins than WCC. By
WCC, the quadruplicate of 2 biological replicates identi-
fied approximately 300 N-glycosylation sites, corre-
sponding to 176 glycoproteins. In contrast, by CMC, the
quadruplicate of 2 biological replicates identified an
average of 670 N-glycosylation sites, corresponding to
374 glycoproteins. Because various LC-MS instruments
and database processing strategies were used, a direct
comparison between 2 approaches might be biased but
might suggest that the wide range of approaches deep-
ened the coverage of the BV-2 N-glycoproteome.
Next, we analyzed the canonical N!P-[S/T/rarely C]
motif in our BV-2 N-glycoproteome (Figure 3C). By
WCC, 2394 (92%) of 2599 N-glycosylation sites matched
the canonical motif without removing the redundancy.
The third position of the canonical motif was occupied
by Thr (612; 58.2%) or Ser (431; 41%) and Thr (830;
58.7%) or Ser (511; 36%) in biological replicates 1 and 2,
respectively. Threonine occurs 1.4-fold more frequently
than serine in mouse glycosylation sites [18], which is
consistent with our data (1.53 = 1442/942). By CMC,
12,889 (76.0%) of 16759 N-glycosylation sites matched
the canonical motif without removing the redundancy
(Figure 4C). The third position of the canonical motif
was occupied by Thr (4477; 47%) or Ser (2826; 30%),
and Thr (3329; 46%) or Ser (2120; 29%) in biological rep-
licates 1 and 2, respectively (Additional file 7: Table S8).
Of 760 N-glycosylated proteins, approximately two-
thirds harbored a single N-glycosylation site (Figure 3D);
17% had 2 N-glycosylation sites, and 9% had 3 sites.Notably, there were 50 glycoproteins that contained 5 or
more N-glycosylation sites and 6 with at least 10 sites. The
highest number of N-glycosylation sites per protein was
25 for prolow-density lipoprotein receptor-related protein
1. Other glycoproteins with 10 or more N-glycosites in-
cluded receptor-type tyrosine-protein phosphatase eta iso-
form 1, plexin B2, nicastrin, toll-like receptor 13, and
lysosome-associated membrane glycoprotein 1.
General characterization of the BV-2 N-glycoproteome
To determine the subset of proteins that was enriched
by N-glyco-FASP, we examined their surface and mem-
brane protein-specific characteristics using various bio-
informatics tools. In the TMD prediction, most identified
proteins had 1 or 2 TMDs (Figure 4A). In addition, 5% of
proteins were predicted to contain a GPI anchor motif by
GPI-SOM [42] and PredGPI [43]. TargetP [44] predicted a
secretion motif in 429 (60%) of all glycoproteins, indicat-
ing that they are cleaved and secreted, despite most glyco-
proteins being membrane-bound (Figure 4A).
According to process of GO analysis in crude mem-
brane proteome, we established a general GO classifica-
tion for all identified glycoproteins (Figure 4B). Our GO
analysis indicated that 75% of N-glycosylated proteins
belonged to the category “membrane;” 66% (506 pro-
teins) matched the category “integral to membrane;” and
only 2% (16 proteins) was annotated as “cytosol” in the
GO cellular compartment (GOCC) term. Moreover, 32%
of the N-linked glycoproteome fell into the “plasma
membrane” category, and 10% was considered “extracel-
lular region” (Figure 4B and Additional file 7: Table S8).
Considering the nonexclusive localization in GO, 42% of
the N-glycoproteome lay on the outside of or beyond
the plasma membrane (321 of 760 N-glycoproteins with
a GO annotation). Nonsurface component categories, in-
cluding the ER (18%), Golgi apparatus (12%), and cyto-
plasmic vesicles (9%), were overrepresented, but in
nearly all cases, these annotations were nonexclusive
(Additional file 7: Table S8) or validated experimentally
as glycoproteins, according to the UniprotKB database.
Figure 4 Functional classification of identified N-glycoproteins. (A) Analysis of transmembrane domains, GPI-anchors, and secretion of
glycoproteins by multiple programs. (B) Gene ontology analysis of identified glycoproteins. Gene ontology of glycoproteins was analyzed using
bioinformatics tools and categorized into 3 groups (cellular component, molecular function, and biological process). Membrane, integral to
membrane, and plasma membrane GO terms are significantly enriched. Furthermore, the molecular function and biological process GO terms are
selectively listed, with a focus on protein classes with functions associated with the sensing of stimuli and transduction of signals at the
membrane.
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glycoproteins were enriched in our dataset, including
receptor activity, transporter activity, TMD receptor ac-
tivity, TMD transporter activity, peptidase activity, and
ion binding. Transport, establishment of localization,
immune function, response to stimulus, biological regu-
lation, and cell adhesion were the predominant overrep-
resented biological processes (Figure 4B and Additional
file 7: Table S8). Most functional categories were linked
to the location of proteins at the membrane. For ex-
ample, transmembrane transporter activity (p < 4.8×10-10)
and cell adhesion (p < 3.7×10-9) were significantly over-
represented. In addition, many glycoproteins in our data
were enriched for immunity (p < 5.1×10-12), which is a
central function of microglia in the brain.
Comparison with existing proteomics and transcriptomics
data
We compared our proteome with published large-scale
proteomes [12,15]. Due to the use of different species of
microglia, it was difficult to compare our identified pro-
teins with those of other studies directly. Thus, we con-
verted the accession numbers in the database to gene
names (symbols) and removed the redundancy of gene
names that resulted from multiple protein isoforms in
each proteome set.
As shown in Additional file 4: Figure S6A, more than
two-thirds of our crude membrane proteome in micro-
glia overlapped with 2 large-scale proteomes [12,15].Nevertheless, approximately 1500 protein groups were
identified as novel proteins in our study. Further, nearly
90% of membrane proteins from an earlier study [12]
were identified as such in our data. These findings dem-
onstrate that our proteome dataset contains many pro-
teins that were not identified in a previous large-scale
proteome analysis of cell lines.
We also compared the N-glycosylation sites in our
study with the largest N-glycoproteome dataset, reported
by Zielinska et al. [18]. The list of 5531 glycosylation
sites from the PHOSIDA database [45] was compared
directly with our N-glycoproteome (1450 sites), based
on mouse IPI accession numbers (IPI_IDs). As shown in
Additional file 4: Figure S6B, of our 1450 N-glycosites,
834 had with the same position, whereas 616 N-glycosyl-
ation sites were unique. Considering the IPI_IDs of gly-
coproteins, 453 IPI_IDs overlapped between the 2
datasets, and 307 of 760 IPI_IDs (40%) were unique to
our study (Additional file 4: Figure S6B).
Our N-glycoproteome was compared with the Uni-
ProtKB database [35]. First, of 3739 mouse proteins that
were annotated as glycoproteins by UniProtKB, 520
overlapped and 240 were identified as new glycoproteins
in our study. Further, N-glycosylation sites were compared
against UniProtKB, which included N-glycosylation infor-
mation of proteins with the qualifiers “Potential,” “By
similarity,” and “Experimental.” The term “Potential” indi-
cates that there is logical or conclusive evidence, based on
sequence analysis software or indirect information. When
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other homologs and isoforms of a protein, it was tagged
with the term “By similarity.”
In our study, 252 N-glycosites, corresponding to 137
glycoproteins, were identified, which has been confirmed
experimentally in previous studies. A total of 740 N-glyco-
sites, corresponding to 384 glycoproteins, were labeled as
“potential” in UniProtKB. Notably, 450 N-glycosites, cor-
responding 349 glycoproteins, were novel N-glycosylation
sites that were uncharacterized in the UniProtKB database
(Additional file 7: Table S8).
Thus, we identified 556 novel N-glycosylation sites that
have not been annotated in PHOSIDA or the UniprotKB
database, most of which were linked to microglial func-
tion. For example, many TLR receptors, including Tlr1,
Tlr2, Tlr4, Tlr7, Tlr9, and Tlr13, were identified in our
crude membrane proteome. In addition, N-glycosites in
Tlr1, Tlr4, Tlr7, Tlr9, and Tlr13 were identified in our N-
glycoproteome. As shown in Additional file 7: Table S8,
many N-glycosylation sites of Toll-like receptors in our
N-glycoproteome have not been reported. We speculate
that these novel sites mediate ligand recognition and regu-
lation of TLR-mediated immune responses and signaling
events.
Finally, to determine whether the N-glycoproteins
were expressed predominantly in mouse microglia, we
examined their expression at the transcriptome level
using BioGPS [46]—705 of all identified glycoproteins
were mapped in the BioGPS database [46], and the gene
expression profiles for normal mouse microglia were com-
pared with those of 96 other normal mouse tissues and
cells [47,48]. Genes in microglia with 2-fold greater ex-
pression versus the median of all 96 tissues and cells were
considered to be expressed specifically in microglia.
A total of 474 (67%) of 704 genes that encoded glyco-
proteins met the filtering criteria; 219 genes (31%) were
constitutively expressed in other mouse tissues and cells.
The expression of 11 genes (1.5%) was lower than in
other mouse tissues and cells. The distribution of this
analysis is shown in Additional file 4: Figure S7, which
shows the expression levels of each gene for the 705
mapped proteins in microglia. Based on these data,
microglia-specific N-glycosylation sites, particularly those
that correspond to the 474 glycoproteins, are attractive
candidate biomarkers and drug targets.
Characterization of TMD-containing proteins and
glycoproteins related to microglial physiology
Because membrane proteins and their glycosylation form
the interface for cellular communication and interaction
with the microenvironment, such as the CNS, an exam-
ination of the function of microglia in the CNS requires
functional classifications to be made for such proteins.
Consistent with the increasing evidence that suggeststhat membrane proteins and their N-glycosylation con-
stitute a major cellular mechanism that regulates micro-
glial function in the brain [3,5,49], we first performed
literature searches and grouped the TMD-containing pro-
teins and N-glycoproproteins in our study into functional
categories using the PANTHER protein class ontology
database [36] (Additional file 4: Figures S8A-C).
Briefly, we performed literature searches to ensure that
our BV-2 proteome as examined as markers for micro-
glia and had functional links to microglial physiology
(Table 2). Nearly all known markers that are used to dis-
criminate microglia from other CNS-resident cells and
monocytes and macrophages were identified in our
study. Also, several N-glycosylation sites in microglia
markers were identified in our N-glycoproteome, allow-
ing us to distinguish microglia from other macrophages
and monocytes in the CNS. Moreover, several significant
membrane proteins in microglial function were identi-
fied in the membrane proteome and N-glycoproteome
(Table 2). The detailed literature search and functional
categories are described in Additional file 3. Also, a de-
tailed list of functional classes for TMD-containing
proteins and N-glycoproteins is provided in Additional
file 8: Table S9.
Pathway analysis of BV-2 crude membrane proteome and
N-glycoproteome
To examine the pathways of the molecular interactions
and reaction networks in our BV-2 membrane proteome
and N-glycoproteome, we analyzed our data using the
KEGG pathways database (Figure 5A). In 6668 proteins
that were enriched in the crude membrane proteome, the
predominant cellular pathways were RNA biogenesis, pro-
tein metabolism, and citric acid (TCA) cycle; neurode-
generative diseases also appeared, such as Huntington,
Parkinson, and Alzheimer diseases. For TMD-containing
proteins that were enriched in crude membrane fractions,
the chief membrane-associated pathways were N-glycan
biosynthesis, lysosome, ABC transporters, and SNARE in-
teractions in vesicular transport. Further, N-glycosylated
proteins were enriched in many pathways that are linked
to the plasma membrane, such as cell adhesion molecules
(CAMs), ECM-receptor interactions, cytokine-cytokine
receptor interactions, and Toll-like receptor signaling
(Additional file 8: Table S10).
An additional pathway analysis was performed using
the PANTHER database [36] to study signaling pathways
(Figure 5B and Additional file 8: Table S11). The crude
membrane proteome was significantly enriched in many
pathways in neurodegenerative diseases and microglia-
mediated inflammation (Figure 5B). Detailed information
on these signaling pathways is described in Additional
file 3. We also detected N-glycoproteins that are associ-
ated with microglia-associated immune responses. For
Table 2 List of membrane proteins and N-glycosylation sites associated with microglial physiology
Group Protein type Representing name Gene symbol Protein name N-glycosites (*Noble site) Max. sequence
coverage
Microglia marker CD11b Itgam Integrin alpha- 58 N, 391 N, 696 N, 734 N, 907 N,
941 N, 1022 N, 1045 N
13.2% (B1)
CD18 Itgb2 Integrin beta-2 51 N, 502 N, 626 N, 644 N 29.8% (B2)
CD11c Itgax Integrin alpha-X 393 N* Glycol-only
Ptprc Receptor-type tyrosine-protein phosphatase C 210 N*, 215 N*, 247 N*, 268 N*,
279 N*, 290 N*, 304 N*, 311 N*,
322 N*, 347 N*, 384 N*, 427 N*,
446 N*, 489 N*, 1237 N*
27.9% (B2)
CD68 Cd68 Macrosialin 129 N*, 134 N*, 169 N*, 178 N, 260 N 16.1% (B2)
F4/80 antigen Emr1 EGF-like module-containing mucin-like
hormone receptor-like 1
405 N*, 413 N*, 417 N*, 498 N 21.3% (B2)
Iba1 Aif1 Allograft inflammatory factor 1 - 8.2% (B2)
Ion channel Calcium channel TRPs Trpm7 Transient receptor potential cation channel
subfamily M member 7
- 1.7% (B1)
Trpc2 Short transient receptor potential channel 2 - 0.8% (B1)
Trpc4 Short transient receptor potential channel 4 - 0.8%(B1)
Trpv2 Transient receptor potential cation channel
subfamily V member 2
567 N* 33.1%(B1)
Potassium channel Inward rectifier
potassium channels
Kcnj2 Inward rectifier K(+) channel Kir2.1 - 3.3%(B1)
BK channels Kcnma1 Calcium-activated potassium channel
subunit alpha-1
- 1.6%(B2)
Kcnu1 Calcium-activated potassium channel
subunit alpha-3
339 N* Glyco-only
Kcnmb3 Calcium-activated potassium channel
subunit beta-3
- 4.6%(B2)
Kcnab2 Voltage-gated potassium channel
subunit beta-2
- 8.6%(B2)
anion channels CLIC-1 chloride
channels
Clic1 Chloride intracellular channel protein 1 - 60.6%(B2)
other channels Proton channels Hvcn1 Hydrogen voltage-gated channel 1 - 13.4%(B1)
Neuro-Trans-mitter
Receptor
Purino ceptors P2X4 P2rx4 P2X purinoceptor 4 75 N, 131 N, 153 N*, 184 N, 208 N 21.6%(B2)
P2X7 P2rx7 P2X purinoceptor 7 74 N, 187 N, 202 N, 213 N 12.8%(B1)
P2Y6, P2Y10 P2ry6 P2Y purinoceptor 6 - 3.7%(B1)
A630033H20Rik Novel protein similar to purinergic receptor
P2Y G-protein coupled 10 (P2ry10)
- 3.7%(B1)




















Table 2 List of membrane proteins and N-glycosylation sites associated with microglial physiology (Continued)
Metabotropic glutamate
receptors
Grm1 Isoform 1 of Metabotropic glutamate
receptor 1
- 2%(B1)






Glucocorticoid receptors Glucocorticoid receptor Nr3c1 Glucocorticoid receptor - 4.2%(B1)
Opioid receptors Sigmar1 Sigma 1-type opioid receptor - 43.5%(B2)
Ogfr Opioid growth factor receptor - 17.1%(B2)
Cytokine receptors TNF-alpha receptors Tnfr2 TNF-alpha receptor 2 - 9.5%(B1)
Tnfrsf1b TNF receptor superfamily member 1B - 9.5%(B1)
Tnfrsf26 TNF receptor superfamily member 26 136 N* 14.2%(B1)
Interleukin receptors Il2rg Interleukin 2 receptor, gamma chain 96 N, 159 N*, 164 N*, 306 N* 5.1%(B1)
Il10rb Interleukin-10 receptor subunit 2 51 N* 11.4%(B1)
Il13ra1 Interleukin-13 receptor subunit alpha-1 262 N Glyco-only
Il6st Interleukin-6 receptor subunit beta 43 N Glyco-only
Il10ra Interleukin-10 receptor subunit alpha 113 N* Glyco-only
Il4ra Isoform 1 of Interleukin-4 receptor
subunit alpha
163 N Glyco-only
Csf2rb Cytokine receptor common subunit beta 141 N* 2.7%(B1)
Other receptor system Notch receptors Notch2 neurogenic locus notch homolog protein 2 - 3.3%(B1)








factor receptor subunit alpha
132 N*, 165 N, 269 N* Glyco-only
Formyl peptide receptors Fpr1 fMet-Leu-Phe receptor - 9.3%(B2)
CD200 receptors Cd200r1 CD200 cell surface glycoprotein receptor 93 N, 192 N* 5.5%(B1)




















Figure 5 Pathway enrichment analysis for identified membrane proteins, transmembrane-containing proteins, and N-glycoproteins.
Pathway enrichment analysis of 3 clusters—crude membrane proteome, transmembrane domains (TMDs), and N-glycoproteins—using the KEGG
pathway database (A) and Panther pathway database (B). Logarithmic corrected p-values for significant overrepresentation are shown. The
number of proteins in each pathway is indicated to the right and left of the bars. Each cluster is indicated by a colored box.
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http://www.biomedcentral.com/1471-2164/15/95example, we noted many N-glycosites on proteins that
are involved in Toll receptor signaling, integrin signaling,
and chemokine- and cytokine-mediated inflammation
(Figure 5B). In particular, Toll receptor signaling is dis-
cussed in Additional file 3. Because N-glycosylation is in-
volved in many processes that are associated with
microglial function in the CNS, such as cell-cell and
receptor-ligand interactions and immune responses, we
hypothesize that N-glycosylation mediates microglia-
induced innate immunity [49].
Multiplexed proteomic CD antigen phenotyping based on
membrane proteins and N-glycosylation
Cluster of differentiation (CD) antigens are cell surface
molecules that are used to immunophenotype cells [50].
Because much disease pathogenesis and progression in-
volve immune system activation or suppression, these
antigens are a unique tool to monitor host responses
[51]. Further, multiplexed phenotyping that involves par-
allel measurements of CD antigens can help identify ex-
pression pattern signatures that are associated with
specific disease states [51].
Multiplexed CD phenotyping of immune cells has trad-
itionally depended on well-characterized monoclonal
antibodies. However, antibody-based approaches are com-
monly restricted to the few existing antibodies. Thus, we
performed multiplexed proteomic CD antigen phenotyp-
ing using data from the MS-based membrane proteome
and N-glycoproteome; 114 CD proteins were expressed
under normal conditions in BV-2 cells (Figure 6).
Sixty-two CDs were identified with greater than 3
unique peptides per CD in at least 1 biological set,whereas 16 proteins were identified by N-glycosylated
peptides. Notably, 78% (89 proteins) of CD antigens were
glycosylated, and 54% (61 proteins) was multiply glyco-
sylated, demonstrating the robustness of cell surface
phenotyping with our proteomics approaches—ie, crude
membrane fractionation and enrichment of N-glycosylation
sites. The identified CD antigens included well-known
microglia surface markers, such as CD11b, CD11c, CD45,
and CD68 [5]. Moreover, CD169 (sialoadhesion), CD204
(MSR), and CD206 (mannose receptor), which are targets
for recognizing macrophages and macrophage-like cells,
were identified. Many CD antigens were highly expressed,
including CD14, CD36, CD39, CD40, CD45, CD47, CD54,
and CD106, which are linked to microglial activation and
microglial functions in immune responses and neurode-
generative diseases.
Consequently, our data confirmed the expression of 114
CD antigens in microglia experimentally, which can be
used to select and evaluate antibodies in microglial func-
tional studies. In addition to Antibody-based applications,
our data allow one to choose fragment ions of peptides
and glycopeptides for MS workflows by peptide-targeted
selected reaction monitoring (SRM) assay [52]. The com-
bination of crude membrane fractionation and N-
glycoprotein enrichment with quantitative SRM assays
will contribute significantly to the comprehensive and sys-
tematic validation of changes in the abundance of targeted
cell surface proteins. Also, such approaches that enable
one the systematically compare cell surface phenotypes
under various conditions have the potential to improve
the classification of and examine surface proteins that
have clinical interest in neurodegenerative diseases.
Figure 6 Extensive CD antigen phenotyping of BV-2 cells. Overview of 114 CD antigens identified in BV-2 cells by crude membrane fractionation
and N-glycopeptide capture. The inner color code of the squares denotes the number of assigned unique peptides per CD antigen for 2 biological
replicates of the crude membrane proteome. Also, the inner color code of the red squares denotes the number of unique N-glycosylation sites per CD
antigen for the N-glycoproteome in BV-2 cells.
Figure 7 Western blot analysis of membrane proteins and N-glycosylated proteins. The abundance of 5 proteins that are closely associated
with microglial functions (A) and 7 membrane and N-glycosylated proteins and 1 cytosolic protein (B) was measured by western blot in control
(RIPA) and crude membrane fraction samples.
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proteome and N-glycoproteome by western blot analysis
Using antibodies and western blot analysis, the major
proteins that were identified in our crude membrane
proteome and N-glycoproteome were validated. The
abundance of 5 major proteins (Cd11b, Cd68, Tlr2,
Tlr13, and P2rx4) that were closely associated with
microglial function increased after crude membrane
fractionation (Figure 7A). Further, several membrane
proteins and N-glycosylated proteins (Ctnnb1, Abcc8,
Stat3, Basp1, Acadvl, Prkar1a/b, and Flnb) were detected
in the crude membrane-enriched fractions. In addition,
the cytosolic protein (Gapdh) was used as a control for
crude membrane fractionation (Figure 7B). Collectively,
these data suggest that our crude membrane fraction-
ation strategies are useful methods for studying mem-
brane proteins and N-glycosylated proteins in microglia.
Conclusion
We performed large-scale analyses of membrane pro-
teins and N-linked glycopeptides from the BV-2 micro-
glia cell line. Without extensive peptide fractionation or
MUDPIT analysis, our combination of sample preparation
methods—crude membrane fractionation, FASP-based
peptide preparation, glycopeptide enrichment using N-
glyco-FASP, and integration of heterogeneous datasets at a
high accuracy level—allowed us to identify 2850 mem-
brane proteins and 1450 unique N-glycosylation sites on
760 glycoproteins, resulting in the identification of 6928
protein groups in BV-2 cells.
Our study is the most comprehensive analysis of the
membrane proteome and N-glycoproteome in microglia,
providing a rich resource that can be used to examine
the functions of membrane proteins and their N-linked
glycosylation with regard to microglial activities in the
brain, including microglial activation, cell-to-cell commu-
nication, innate immune responses, and inflammatory ac-
tivity. Further, information on novel N-glycosylation sites
and N-glycosylation sites that are involved in microglial
immune responses can be used by ongoing clinical studies
on the membrane proteome or N-glycoproteome to target
microglial proteins that mediate the pathology of neuro-
logical diseases.
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